There is no additional evidence found since a previous 2015 CADTH review that found no evidence on the clinical effectiveness and the cost-effectiveness of rituximab compared with active or no treatment for remission maintenance in patients with GPA and MPA.¹¹ Similar to uncontrolled studies reported in the previous CADTH review, recent uncontrolled studies (Appendix 2) on the use of rituximab as maintenance therapy for GPA and MPA^5,6 found some value of rituximab in reducing relapses and maintaining remission, but the lack of a comparator group made comparison to other immunosuppressive drugs impossible. Randomized controlled trials comparing rituximab to other immunosuppressive drugs for remission maintenance in patients with GPA and MPA are needed. No evidence was found on cost-effectiveness and no evidence-based guidelines regarding the use of rituximab for patients with GPA and MPA were identified.